Healthcare company Zimmer Biomet Holdings Inc (NYSE:ZBH) (SIX:ZBH) revealed on Friday the receipt of approval from the US Food and Drug Administration approval for The Tether for the fusion-less alternative surgery in young patients with scoliosis requiring surgery.
According to the company, the current surgical treatment for scoliosis is an invasive operation involving large incisions, extensive soft tissue disruption and restriction of spinal motion with metal rods inserted along both sides of the spine to secure and align the vertebrae.
The Tether, the company's anterior vertebral body tethering (AVBT) solution, uses a strong, flexible cord, rather than metal rods, to pull on the outside of a scoliosis curve to initially straighten the spine, while the inside of the curve is left free to grow. Additionally, unlike fusion metallic rods, The Tether is positioned utilizing an endoscopic minimally invasive approach through a few small openings between the ribs.
In conjunction, The Tether is available through the US FDA's humanitarian device exemption (HDE) pathway.
Under a collaboration with the US FDA and the Harms Study Group, a worldwide cohort of surgeons, the company will launch and perform a comprehensive, multi-centre, prospective research studies focused on pediatric spinal deformity.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial